Analysts’ Opinions Are Mixed on These Healthcare Stocks: Incyte Corp (NASDAQ: INCY), ImmunoGen (NASDAQ: IMGN) and Radius Health (NASDAQ: RDUS)

By Austin Angelo

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Incyte Corp (NASDAQ: INCY), ImmunoGen (NASDAQ: IMGN) and Radius Health (NASDAQ: RDUS).

Incyte Corp (NASDAQ: INCY)

Cowen & Co. analyst Eric Schmidt reiterated a Buy rating on Incyte Corp (NASDAQ: INCY) yesterday. The company’s shares opened today at $124.03.

Schmidt commented:

“Over the weekend Incyte presented multiple datasets from a Phase I/II trial of.”

According to TipRanks.com, Schmidt is a top 100 analyst with an average return of 25.8% and a 56.7% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Merrimack Pharmaceuticals, and Threshold Pharmaceuticals.

Currently, the analyst consensus on Incyte Corp is Strong Buy and the average price target is $151.38, representing a 22.1% upside.

In a report released today, BMO Capital also reiterated a Buy rating on the stock with a $166 price target.
ImmunoGen (NASDAQ: IMGN)

Cowen & Co. analyst Boris Peaker reiterated a Hold rating on ImmunoGen (NASDAQ: IMGN) yesterday. The company’s shares opened today at $5.05.

According to TipRanks.com, Peaker is a 3-star analyst with an average return of 1.3% and a 38.5% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Corvus Pharmaceuticals Inc, and Merrimack Pharmaceuticals.

Currently, the analyst consensus on ImmunoGen is Moderate Buy and the average price target is $6, representing a 18.8% upside.

In a report issued on May 23, Cantor Fitzgerald also reiterated a Hold rating on the stock with a $5 price target.
Radius Health (NASDAQ: RDUS)

In a report released today, John Newman from Canaccord Genuity reiterated a Buy rating on Radius Health (NASDAQ: RDUS), with a price target of $85. The company’s shares opened today at $38.75.

According to TipRanks.com, Newman is ranked 0 out of 5 stars with an average return of -6.5% and a 34.7% success rate. Newman covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, Hutchison China MediTech Ltd, and Synergy Pharmaceuticals Inc.

Currently, the analyst consensus on Radius Health is Moderate Buy and the average price target is $54.20, representing a 39.9% upside.

In a report issued on May 22, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $65 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.